text_1: Sylentis announces the results of tivanisiran for dry eye syndrome
text_2: This news release focuses on a study of a new drug, tivanisiran, to treat dry eyes that was presented at a recent medical conference. It mentions the completion of both phase I and phase 2 trials and the start of a phase 3 trial, but it neglects to provide any of the details of the research. There is nothing offered about costs, the benefits or the harms of using the drug. It refers to the terms of “dry eye disease” or “dry eyes syndrome” repeatedly even though these are not recognized medical conditions. When it comes to health and medical news, journalists and other members of the public deserve useful information that can be used to evaluate a new treatment. The research summarized here is in far too early a stage to warrant distributing a news release.